HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
暂无分享,去创建一个
D. Richman | B. Larder | G. Darby | D D Richman | B A Larder | G Darby
[1] F. Schmitt,et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. , 1988, The New England journal of medicine.
[2] B. Chesebro,et al. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity , 1988, Journal of virology.
[3] D. Richman,et al. Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. , 1988, The American journal of medicine.
[4] D. Richman,et al. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. , 1988, The Journal of biological chemistry.
[5] D. Mack,et al. Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). , 1988, Annals of internal medicine.
[6] J. Craig,et al. ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRUS INFECTION DUE TO ALTERED DNA POLYMERASE , 1987, The Lancet.
[7] J. Pagano,et al. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine , 1987, Journal of virology.
[8] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[9] Brendan A. Larder,et al. Site-specific mutagenesis of AIDS virus reverse transcriptase , 1987, Nature.
[10] S. Broder,et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases , 1987, Clinical pharmacology and therapeutics.
[11] B. Larder,et al. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities. , 1985, Virology.
[12] N. Yamamoto,et al. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. , 1985, Science.
[13] J. Meyers,et al. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. , 1983, The Journal of infectious diseases.
[14] H. Prentice,et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. , 1983, British medical journal.
[15] O. Laskin,et al. ISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY , 1982, The Lancet.
[16] H. Field,et al. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance , 1981, Nature.
[17] H. Field,et al. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo , 1980, Antimicrobial Agents and Chemotherapy.